Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gemphire Therapeutics
Livonia, Michigan, United Statesgemphire.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Other
01
Overview
Gemphire Therapeutics developed gemcabene, a once-daily oral small molecule therapy, and completed three Phase IIb clinical trials in patients with homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease, and severe hypertriglyceridemia. The company also targeted NAFLD/NASH but revenue was not reported and the company became inactive following acquisition.
- Therapeutic areas
- GastroenterologyCardiovascularMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Gemphire Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gemphire Therapeutics.